Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
  • A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
  • A61L12/12—Non-macromolecular oxygen-containing compounds, e.g. hydrogen peroxide or ozone
  • A61L12/124—Hydrogen peroxide; Peroxy compounds
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
  • A01N25/08—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
  • A01N25/10—Macromolecular compounds
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
  • A01N59/08—Alkali metal chlorides; Alkaline earth metal chlorides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
  • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
  • A61K31/716—Glucans
  • A61K31/717—Celluloses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/40—Peroxides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0048—Eye, e.g. artificial tears
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
  • A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics

Definitions

• the present invention relates to a method of preserving ophthalmic solutions with trace amounts of stabilized peroxy compounds and alkaline earth metal salts.
• Trace amounts of peroxy compounds stabilized with a hydrogen peroxide stabilizer especially diethylene triamine penta(methylene phosphonic acid) or 1-hydroxyethylidene-1,1-diphosphonic acid may be utilized as a preservative for eye wetting solutions, eye lubricating solutions, or ophthalmic active agent-containing solutions to be used in the ocular environment.
• Ophthalmic active agent-containing solutions contain at least one medicinal agent for application directly to the eye.
• the preservative according to the present invention may be used in any ophthalmic solution as long as the ingredients in that solution are compatible with trace amounts of the peroxy compounds.
• a hydrogen peroxide source is any peroxy compound that is hydrolyzed in water to produce hydrogen peroxide.
• hydrogen peroxide sources which provide an effective resultant amount of hydrogen peroxide
• examples of hydrogen peroxide sources include sodium perborate decahydrate, sodium peroxide and urea peroxide. It has been found that peracetic acid, an organic peroxy compound, cannot be stabilized utilizing the present system.
• Ophthalmic active agents are compounds that have a pharmacological effect on the eye when administered topically to the eye.
• the following is a non-exhaustive, non-limiting, illustrative list of ophthalmic active agents and excipients that are compatible with the preservative according to the present invention: atropine, homatropine, cyclopentolate, tropicamide, lachesine, dibutoline, oxyphenonium, eucatropine, ephedrine, carbachol, methacholine, pilocarpine hydrochloride, isoflurophate, physostigmine, neostigmine, lignocaine, cocaine, acetylcholine chloride, antazoline phosphate, betaxolol hydrochloride, demecarium bromide, dipivefin hydrochloride, erythromycin,
• An ophthalmic demulcent means a water-soluble agent, that is applied topically to the eye to protect and lubricate mucous membrane surfaces and relieve dryness and irritation.
• ophthalmic demulcents are cellulose derivatives such as carboxymethylcellulose and salts thereof, hydroxyethyl cellulose, hydroxypropyl methylcellulose, and methylcellulose; dextran 70; gelatin; polyols such as glycerin, polyethylene glycol 300, polyethylene glycol 400, polysorbate 80, and propylene glycol; polyvinyl alcohol; and povidone.
• Excipients of various types compatible with the present invention include, but are not limited to polysorbate gelatin (Tween), dextrans, lanolin inositol phosphates, alkylsulfosuccinates, sulfosuccinamates, alkyl silicone sulfosuccinates, alkylpolyether carboxylates, alkylaryl polyethoxylamines, alkylarylsulfonates, alpha olefin sulfonates, alkyl sulfates, alkyl ether sulfates, alkanol amides and alkamides, alkylamphoterics, amphoterics based on alkyl imidazoline, betaines, alkylaminopropionates, alkyliminodipropionates, alkylamphoglycinates, alkylamphocarboxyglycinates, alkylamphocarboxypropinates, alkylamphopropionates,
• Such compounds believed not compatible with trace stabilized hydrogen peroxide include: noradrenaline, adrenaline, phenylephrine hydrochloride, amethocaine, oxybuprocaine, proxymethacaine, cromolyn sodium, benoxinate hydrochloride, chloramphenicol, chlortetracycline hydrochloride, dexamethasone, dichlorphenamide, echotiophate iodide, epinephrine bitartrate, fluorometholone, gramicidin, hydrocortisone, methazolamide, natamycin, prednisolone acetate, sulfacetamide (N 1 -acetylsulfanilamide), tetracycline hydrochloride and timolol maleate.
• a hydrogen peroxide stabilizer means any of the known stabilizers of peroxy compounds including phosphonates, phosphates, stannates, etc.
• Physiologically compatible salts of phosphonic acids may also be used, such as diethylene triamine penta(methylene-phosphonic acid and physiologically compatible salts thereof and 1-hydroxyethylene-1,1-diphosphonic acid and physiologically acceptable salts thereof.
• Other stabilizers of peroxy compounds useful in the practice of the present invention are disclosed in U.S. Pat. No. 5,725,887 at, inter alia, column 5, line 55 to column 6, line 34.
• stannate stabilizers are to be avoided as they tend to “cloud” the lens material.
• the peroxy stabilizer is diethylene triamine penta(methylene-phosphonic acid
• it can be present in the solution in an amount between about 0.001 and about 0.02% by weight of the solution, or in an amount between about 0.006 and about 0.012% by weight of the solution.
• the peroxy stabilizer is 1-hydroxyethylene-1,1-diphosphonic acid it can be present in the solution in an amount between about 0.005 and about 0.2% by weight of the solution.
• Stabilizers other than diethylene triamine penta(methylene-phosphonic acid and physiologically compatible salts thereof and 1-hydroxyethylene-1,1,-diphosphonic acid and physiologically acceptable salts thereof are employed in physiologically tolerable amounts.
• Soluble alkaline earth metal salts can be used in the compositions and methods of the present invention in amounts between about 0.01 and 0.2% by weight of the preserved solution, or between about 0.05 and 0.1% by weight of the preserved solution.
• Water soluble salts of magnesium and calcium are such alkaline earth metal salts.
• Preserved solutions comprising about 0.05% and 0.1% alkaline earth metal salts are disclosed herein. The present inventor has discovered that addition of such soluble alkaline earth metal salts increases antifingal preservative efficacy in ophthalmic solutions preserved with low amounts of hydrogen peroxide.
• the pH of the stabilized solution is between about 5.5 and about 8.
• the pH of a stabilized hydrogen peroxide solution is between about 6.0 and 8.0, most preferable between about 6.5 and 7.5.
• the pH can be adjusted as desired by incorporation of suitable amounts of acid or base of a physiologically tolerable nature in the amounts employed, e.g. hydrochloric acid and sodium hydroxide.
• Suitable such agents include, for example, mannitol, sorbitol, glycerol, alkali metal halides, phosphates, hydrogen phosphate, and borates, such as sodium chloride, sodium phosphate monobasic and sodium phosphate dibasic.
• the function of such tonicity enhanging agents is to assure approximate physiologic tonicity to the solution which is instilled in the eye or to help assure such tonicity upon dilution if dilution is necessary prior to contact with the eye due to peroxide content as indicated above.
• tonicity enhancing agents are present in the solution so that it is substantially isotonic or, such that, upon decomposition or dilution of the hydrogen peroxide therein, the resulting solution is substantially isotonic, e.g. subtantially equivalent in tonicity to a 0.9% by weight aqueous sodium chloride solution.
• a further optional ingredient is a thickener or viscosity enhancing agent.
• a thickener or viscosity enhancing agent Any of the substances known in these categories which are ocularly acceptable can be used.
• suitable thickeners include, inter alia, polyvinylalcohol, hydroxy ethylcellulose, etc. Thickeners may be present in any amount up to an amount sufficient to raise the overall solution viscosity to about 1000 cps, preferably to not more than 100 cps.
• the stabilized hydrogen peroxide solutions of the present invention are characterized by their extraordinary stability, even under accelerated conditions, for example by heating the solutions to 100° C. for 24 hours. Thus, the shelf life of these compositions is enhanced. Moreover, the instant compositions are characterized by either physiological tolerability subsequent to hydrogen peroxide decomposition.
• Formulation of the solutions of the invention can be made in any conventional manner.
• all of the components other than the hydrogen peroxide and water can be placed in a container and fresh, preferably concentrated, hydrogen peroxide added thereto with mixing.
• the dry components can be rubbed up with a small portion of liquid stabilizer, then the remainder of the stabilizer added, followed by the hydrogen peroxide, and most of the water.
• the viscosity enhancing agent i.e. thickener, can then be added or the formed solution can be added to the thickener.
• One of ordinary skill in the art will be aware of numerous variations in the manner of formulating the solutions of the invention.
• Additional physiological compatible peroxide neutralizing agents include reducing agent such as pyruvic acid and suitable salts thereof such as the sodium salt.
• a solution with the following composition is prepared by admixing the following components to form a solution.
• HPMC Hydropropylmethylcellulose, E50LV, from Dow Chemical, USP grade
• Tonicity 220+/ ⁇ 15 mOsm/kg
• a solution with the following composition is prepared by admixing the following components to form a solution.
• HPMC Hydropropylmethylcellulose
• Tonicity 220+/ ⁇ 15 mOsm/kg
• a solution with the following composition is prepared by admixing the following components to form a solution.
• HPMC Hydropropylmethylcellulose
• Tonicity 220+/ ⁇ 15 mOsm/kg

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Inorganic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Wood Science & Technology (AREA)
• Dentistry (AREA)
• Environmental Sciences (AREA)
• Zoology (AREA)
• Plant Pathology (AREA)
• Agronomy & Crop Science (AREA)
• Pest Control & Pesticides (AREA)
• Ophthalmology & Optometry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Molecular Biology (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Toxicology (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=23375570

Family Applications (2)

Family Applications After (1)

Country Status (22)

Families Citing this family (7)

Citations (3)

Family Cites Families (10)

• 2003
  • 2003-01-16 US US10/346,013 patent/US20070092582A1/en not_active Abandoned
  • 2003-01-16 AR ARP030100122A patent/AR038299A1/es unknown
  • 2003-01-16 TW TW092100882A patent/TWI357331B/zh not_active IP Right Cessation
  • 2003-01-16 PE PE2003000048A patent/PE20030729A1/es not_active Application Discontinuation
  • 2003-01-17 IL IL16259303A patent/IL162593A0/xx unknown
  • 2003-01-17 KR KR10-2004-7011046A patent/KR20040074121A/ko not_active Application Discontinuation
  • 2003-01-17 BR BR0306873-0A patent/BR0306873A/pt not_active Application Discontinuation
  • 2003-01-17 EP EP03702459A patent/EP1469732A1/en not_active Ceased
  • 2003-01-17 PL PL369724A patent/PL210869B1/pl not_active IP Right Cessation
  • 2003-01-17 KR KR1020107014527A patent/KR20100080951A/ko not_active Application Discontinuation
  • 2003-01-17 WO PCT/EP2003/000450 patent/WO2003059069A1/en active Application Filing
  • 2003-01-17 MX MXPA04006916A patent/MXPA04006916A/es active IP Right Grant
  • 2003-01-17 AU AU2003205620A patent/AU2003205620B2/en not_active Ceased
  • 2003-01-17 RU RU2004125284/15A patent/RU2359706C2/ru not_active IP Right Cessation
  • 2003-01-17 NZ NZ533967A patent/NZ533967A/en not_active IP Right Cessation
  • 2003-01-17 JP JP2003559245A patent/JP2005514428A/ja not_active Withdrawn
  • 2003-01-17 MY MYPI20030154A patent/MY136548A/en unknown
  • 2003-01-17 CN CNB038023350A patent/CN100341412C/zh not_active Expired - Fee Related
  • 2003-01-17 CA CA2470396A patent/CA2470396C/en not_active Expired - Fee Related
• 2004
  • 2004-06-07 ZA ZA200404468A patent/ZA200404468B/en unknown
  • 2004-06-17 IL IL162593A patent/IL162593A/en not_active IP Right Cessation
  • 2004-06-18 EC EC2004005164A patent/ECSP045164A/es unknown
  • 2004-08-09 NO NO20043307A patent/NO20043307L/no not_active Application Discontinuation
  • 2004-08-17 CO CO04079839A patent/CO5601034A2/es not_active Application Discontinuation
• 2010
  • 2010-11-08 JP JP2010249884A patent/JP2011026350A/ja active Pending
• 2011
  • 2011-02-11 US US13/026,018 patent/US20110135752A1/en not_active Abandoned

Patent Citations (4)

Also Published As

Similar Documents

Legal Events